HONG KONG, Feb 11, 2025 – (ACN Newswire) – On Feb. 9, 2025, the official website of the Center for Drug Evaluation, National Medical Products Administration of China indicates that the Biologics License Application (BLA) for Luzhu Biotech’s (2480.HK) biological product for prophylaxis, Recombinant Herpes Zoster Vaccine (CHO Cells…
Read More
